Jarvik R K, DeVries W C, Semb B K, Koul B, Copeland J G, Levinson M M, Griffith B P, Joyce L D, Cooley D A, Frazier O H
J Heart Transplant. 1986 May-Jun;5(3):184-95.
The Jarvik-7 total artificial heart has been implanted in 18 patients at the time of this writing. Eleven patients received the 100 ml heart, and the remaining seven were treated with the 70 ml device. To date, five patients have been implanted for permanent use with an average survival in excess of 9 months, and the longest survival is more than 1 1/2 years following implantation of the heart. Complications related to positioning were a contributing factor in the death of one patient. Thirteen patients have received the Jarvik-7 heart as a bridge to transplant. Three died before transplant, and the remaining ten have been transplanted. To date, all are alive, several are home and in excellent condition, and several are still hospitalized but are expected to be released shortly. Three patients have experienced serious complications after transplantation. One patient rejected her heart transplant, was reimplanted with the artificial heart, and now has been sustained for more than 3 months. At this time she is in good condition awaiting a second donor. Selection of the appropriate size Jarvik-7 artificial heart for the individual patient can best be made based on measurements of thoracic dimensions obtained from a computed tomography scan and calculation of body surface area. The appropriate medial or lateral positioning can be determined and decisions concerning the lengths of the grafts and cuffs, excision or nonexcision of the left pericardium, and air drive line position can be made. The Jarvik-7 heart can be successfully used in patients from 50 kg. However, at the lower size limit in patients from approximately 50 to 65 kg, the risk of fit complications is the greatest and availability of an even smaller model heart would be desirable.
撰写本文时,已有18名患者植入了贾维克-7型全人工心脏。11名患者植入的是100毫升的心脏,其余7名患者使用的是70毫升的装置。迄今为止,有5名患者植入后长期使用,平均存活时间超过9个月,存活时间最长的患者在植入心脏后已超过1年半。与心脏植入位置相关的并发症是导致1名患者死亡的一个因素。13名患者植入贾维克-7型心脏作为移植过渡手段。3名患者在移植前死亡,其余10名患者已接受移植。迄今为止,这些患者均存活,其中几名已回家且状况良好,还有几名仍住院,但预计不久后即可出院。3名患者在移植后出现了严重并发症。1名患者的心脏移植被排斥,再次植入人工心脏,目前已维持了3个多月。此时她状况良好,正在等待第二位供体。为个体患者选择合适尺寸的贾维克-7型人工心脏,最好根据计算机断层扫描获得的胸廓尺寸测量值以及体表面积计算结果来确定。可以确定合适的内侧或外侧位置,并就移植物和袖带的长度、是否切除左心包以及空气驱动管的位置做出决定。贾维克-7型心脏可成功用于体重50千克以上的患者。然而,对于体重约50至65千克的患者,在尺寸下限处出现适配并发症的风险最大,因此希望能有更小型号的心脏可供使用。